2 22012 Annual Report

2

Our MissiOnThe V Foundation is a charitable organization dedicated to saving lives by helping to find a cure for cancer. The Foundation seeks to make a difference by generating broad-based support for cancer research and by creating an urgent awareness among all Americans of the importance of the war against cancer. The Foundation performs these dual roles through advocacy, education, fundraising, and philanthropy.

The V Foundation awards three types of grants. The V Scholar Grant provides funds directly to young scientists to establish their own independent laboratory. The Translational Grant facilitates the transition of projects from the laboratory to the clinic. The Designated Grant funds projects in communities or regions local to the fundraising area.

2012 grants awarded

3

Unhee Lim, Ph.D.University of Hawaii Cancer CenterHonolulu, HIInvestigating global leukocyte DNA methylation for predicting colorectal cancer risk in a multiethnic population

Mohammad (Mo) Motamedi, Ph.D.Massachusetts General Hospital Cancer CenterCharlestown, MAThe role of sirtuins in epigenetics and genomic stability

Trudy G. Oliver, Ph.D.Huntsman Cancer Institute University of UtahSalt Lake City, UTFunded by the Thomas Carroll Family In memory of Christopher T. Carroll Understanding Myc’s role in small cell lung cancer

Asha Bhaskaran Pillai, M.D.St. Jude Children’s Research HospitalMemphis, TNAugmenting cytotoxicity of ex vivo expanded human iNKT cells for cancer immunotherapy

Jeffrey W. Tyner, Ph.D.Knight Cancer InstituteOregon Health and Science UniversityPortland, ORTranslation of novel mutations in CSF3R into validated therapeutic modalities

Christopher R. Vakoc, M.D., Ph.D.Cold Spring Harbor LaboratoryCold Spring Harbory, NYTherapeutic targeting of the polycomb complex PRC2 in acute myeloid leukemia

2012 V schOlars

Hiu Wing Cheung, Ph.D.Hollings Cancer CenterMedical University of South CarolinaCharleston, SCRole of ID4 in ovarian cancer development and metastasis

Christina Curtis, Ph.D.USC Norris Comprehensive Cancer CenterUniversity of Southern California Los Angeles, CAInterrogating patient-specific tumor dynamics through single cell profiles and computational modeling

Todd Fehniger, M.D., Ph.D.Siteman Cancer CenterWashington University School of MedicineSt. Louis, MOEnhanced innate immunity to cancer utilizing human memory-like NK cells Daniel A. Harki, Ph.D.Masonic Cancer CenterUniversity of MinnesotaMinneapolis, MNFunded by Delta Chi Fraternity Beyond parthenolide: next generation molecules targeting AML cancer stem cells

Justin D. Lathia, Ph.D.Cleveland Clinic Lerner College of MedicineCleveland, OHAlbert Wyrick V Scholar AwardFunded by the Michael and Carole Marks Family Holding on to stemness: targeting mechanisms that maintain glioblastoma stem cells

Qing Li, M.D., Ph.D.University of Michigan Comprehensive Cancer CenterUniversity of Michigan Ann Arbor, MINRAS signaling in hematopoietic stem cells and leukemic stem cells

Jeffrey Venstrom, M.D.UCSF Helen Diller Family Comprehensive Cancer CenterUniversity of California at San FranciscoSan Francisco, CAFunded by The V Foundation Wine Celebration Volunteer GrantIn honor of Derek and Cathy ReisingerMechanisms and strategies for recruiting natural killer cells to cure acute myeloid leukemia

Jessie Villanueva, Ph.D.The Wistar InstitutePhiladelphia, PAEstablishing molecular targets for NRAS driven melanomas: an unmet medical need

Sarah (Sadie) Wignall, Ph.D.Robert H. Lurie Comprehensive Cancer CenterNorthwestern University Chicago, ILTargeting centrosome-clustering mechanisms to selectively kill cancer cells

Monte M. Winslow, Ph.D.Stanford Cancer InstituteStanford University Stanford, CAMartin D. Abeoff, M.D. V Scholar Award*Functional characterization of Nkx2-1 regulated genes that govern lung cancer metastasis

Xiaoyang Wu, Ph.D.University of Chicago Comprehensive Cancer InstituteChicago, ILSpectraplakin and coordinated cytoskeletal dynamics in colorectal cancer

*The research project that receives the highest rating by the Scientific Advisory Board will annually be designated as the Martin D. Abeloff, M.D. V Scholar Award.

2012 TranslaTiOnal GranTs

Steven P. Balk, M.D., Ph.D.Huihui Ye, MMSc.Glenn Bubley, M.D.Martin Sanda, M.D.Beth Israel Deaconess Medical CenterBoston, MAMolecular characterization of gleason 3 tumors that progress to gleason 4

Michele Carbone, M.D., Ph.D.Haining Yang, Ph.D.Ian Pagano, Ph.D.University of Hawaii Cancer CenterHonolulu, HIHMGB1: A biomarker for mineral fiber exposure and detection of malignant mesothelioma

Reuben S. Harris, Ph.D.Douglas Yee, M.D.Masonic Cancer CenterUniversity of MinnesotaMinneapolis, MNFunded by The V Foundation Wine Celebration Vintner GrantIn honor of Suzanne Pride-BryanRole of DNA deamination in breast cancer

Nora Heisterkamp, Ph.D.Steven Mittelman, M.D., Ph.D.Yong-mi Kim, M.D., Ph.D.Children’s Hospital Los AngelesLos Angeles, CAImproving treatment outcome in leukemia by disruption of bone-marrow leukemia interactions relevant to minimal residual disease

Angela M. Hartley Brodie, Ph.D.University of Maryland School of MedicineFunded by Friends of V Baltimore Golf ClassicTargeting mechanisms of resistance to hormone therapy in breast cancer

Miaofen G. Hu, M.D., Ph.D.Richard Van Eten, M.D., Ph.D.Tufts Medical CenterMedford, MACDK6 as a novel therapeutic target in T-cell acute lymphoblastic leukemia

Mark C. Lanasa, M.D., Ph.D.Sandeep Dave, M.D., M.S.Duke Cancer InstituteDuke University Medical CenterDurham, NCGenetic determinants of progression in chronic lymphocytic leukemia

Anthony E. Oro, M.D., Ph.D.Jean Y. Tang, M.D., Ph.D.Stanford Cancer InstituteStanford UniversityStanford, CANovel therapies for hedgehog-dependent cancers

W. Kimryn Rathmell, M.D., Ph.D.Jason Lieb, Ph.D.Ian Davis, M.D., Ph.D.UNC Lineberger Comprehensive Cancer CenterUniversity of North Carolina at Chapel HillChapel Hill, NCFunded by the Jimmy V Celebrity Golf Classic In memory of Girard TilleryReprogramming the histone methylation code of renal cell carcinoma

Martine F. Roussel, Ph.D.Amar Gajjar, M.D.St. Jude Children’s Research HospitalMemphis, TNIdentification and pre-clinical testing of compounds to treat group 3 medulloblastoma

4

Kimberly Stegmaier, M.D.James E. Bradner, M.D.Lisa R. Diller, M.D.Dana-Farber Cancer InstituteBoston, MATherapeutic targeting of N-Myc with BET bromodomain inhibition in neuroblastoma

2012 DesiGnaTeD GranTs

All Children’s HospitalDick Vitale Pediatric Cancer Research FellowshipSt. Petersburg, FLFunded by the Dick Vitale Gala

Victoria F. Borges, M.D., MMScUniversity of Colorado Cancer CenterDenver, COFunded by the Kay Yow Cancer FundPilot study the prevention of postpartum pregnancy associated breast cancer

Ian Davis, M.D., Ph.D.UNC Lineberger Comprehensive Cancer Center at UNCFunded by the Jimmy V Celebrity Golf ClassicTargeting deregulated transcription in pediatric cancers

James M. Ford, M.D.Stanford Cancer InstituteStanford UniversityPalo Alto, CAFunded by the Gastric Cancer Foundation

Peter Forsyth, M.D.H. Lee Moffitt Cancer Center and Research InstituteUniversity of South FloridaTampa, FLFunded by the Dick Vitale GalaDeveloping myxoma virus as an experimental treatment for brain cancer stem cells in children and adults with malignant gliomas

Susan Goodin, PharmD.Cancer Institute of New JerseyRobert Wood Johnson Medical SchoolUniversity Medical CenterNew Brunswick, NJFunded by Marketing Research Consultants Prevention of prostate cancer progression by atorvastatin and celecoxib

Ramaswamy Govindan, M.D.Siteman Cancer Center Washington University School of MedicineSt. Louis, MOFunded by UNICO In memory of Dorothy Jean VarsalonaMolecular assay to predict outcomes in resected NSCLC using nanostring technology

Corrine Linardic, M.D., Ph.D.Duke Cancer InstituteDuke University Medical CenterDurham, NCFunded by Apple Gold GroupUnderstanding SFRP’s contribution to alveolar rhabdomyosarcoma tumorigenesis

University of Texas MD Anderson Cancer CenterPediatric CancerFunded by LG Electronics Home Court Advantage

Nehal Parikh, M.D.Connecticut Children’s Medical CenterHartford, CTFunded by ESPN, Inc.Isolation and characterization of cancer stem cells in neuroblastoma tumor model

St. Helena Hospital FoundationSt. Helena, CAFunded by The V Foundation Wine Celebration

University of Texas MD Anderson Cancer CenterHouston, TXSPORE in Ovarian CancerFunded by the Kay Yow Cancer Fund

Daniel S. Wechsler, M.D., Ph.D.Duke Cancer InstituteDuke University Medical CenterDurham, NCFunded by Apple Gold GroupStrike while the iron is not: targeting CALM-rearranged leukemias by iron deprivation

Hai Yan, M.D., Ph.D.Duke Cancer InstituteDuke University Medical CenterDurham, NCSupplemental SPOREFunded by The V Foundation Wine Celebration and Accelerate Brain Cancer CureDeveloping novel approaches to target gliomas

Steven Zeitels, M.D., FACSMassachusetts General Hospital Cancer CenterBoston, MAFunded by the Dick Vitale GalaVoice preservation in the treatment of early glottic (laryngeal) cancer

5

The V Foundation Board of Directors is entrusted with and accountable for the strategic leadership and governance of the organization. The Board is comprised of prominent business leaders, award-winning athletes and coaches, distinguished physicians and world-renowned entertainers. Their governance is integral to the sustainability and long-term effectiveness of the Foundation in ways that are consistent with our core values and principles.

board of directors

Philip H. Knight Chairman of the Board of DirectorsNike, Inc.

Michael W. Krzyzewski Head Coach, Men’s BasketballDuke University

Eric Lautenbach Director of College Basketball Sports MarketingNIKE, Inc.

Carl C. Liebert III PresidentUSAA Capital Corporation

Robert E. Lloyd ChairmanThe V Foundation for Cancer Research

Joe Loughrey Retired President and Vice ChairmanCummins, Inc.

Michael C. Mac Donald Chairman and Chief Executive OfficerMedifast

Michael E. Marks Founding PartnerRiverwood Capital, LLC

Geoffrey S. MasonSenior Production SpecialistESPN, Inc.

Jim AllegroEmeritus DirectorRetired Executive Vice PresidentESPN, Inc. Julie Allegro General PartnerAllegro Venture Partners

Robert C. Bast Jr., M.D.Vice President for Translational ResearchUniversity of Texas MD Anderson Cancer Center

George Bodenheimer Executive ChairmanESPN, Inc.

Steven M. Bornstein President and Chief Executive OfficerNFL Network

Bill Cosby

George W. Dennis IIIRetired Senior PartnerTeague Campbell Dennis & Gorham, LLP

David B. Fay Retired Executive DirectorUnited States Golf Association

Rosa M. Gatti Retired Senior Vice President, Communications Counsel and Corporate OutreachESPN, Inc.

6

Robert ValvanoSports Commentator

Lesley Visser Sports CommentatorCBS and HBO

Dick VitaleSports CommentatorESPN, Inc. and ABC Sports

R.C. “Bucky” WatersRetired Vice Chancellor/Special Projects Duke University Medical CenterSports CommentatorESPN, Inc. & Madison Square Garden

Robert P. Wayman Retired Chief Financial Officer and Executive Vice President Hewlett-Packard Company

Dereck WhittenburgSports CommentatorESPN, Inc.

David W. WilliamsRetired Senior Vice PresidentWhirlpool Corporation

Norby WilliamsonExecutive Vice President, Programming & Acquisitions ESPN, Inc.

Larry WoodardPresident and Chief Executive OfficerGraham Stanley Advertising

Joseph O. Moore, M.D.Medical DirectorDuke Raleigh Cancer CenterProfessor, Hematology & OncologyDuke Cancer Institute

Robert C. NakasoneRetired Chief Executive OfficerToys “R” Us

Donna Orender Chief Executive OfficerOrender Unlimited LLC

Lawrence F. Probst IIIChairman of the BoardElectronic ArtsChairmanUnited States Olympic Committee

Harry E. Rhoads, Jr. Chief Executive OfficerWashington Speakers BureauSecretaryThe V Foundation for Cancer Research

Robin Roberts Co-AnchorABC’s Good Morning America

John P. Saunders Sports CommentatorESPN, Inc. and ABC Sports

Constance E. SkidmoreFormer Board Member and Managing PartnerPricewaterhouseCoopers LLC

John Skipper PresidentESPN, Inc.

Anthony F. Smith, Ph.D.Co-Founder and Managing DirectorLeadership Research Institute

Pamela Valvano StrasserChairwomanThe V Foundation for Cancer Research

Nicholas P. ValvanoPresident Emeritus The V Foundation for Cancer Research

7

The Scientific Advisory Board is comprised of leading physicians and research scientists from prominent universities and cancer centers. The all-volunteer Scientific Advisory Board ensures that grant proposals meet the highest standards of scientific merit and that funding is properly allocated.

scientific advisory board

Richard I. Fisher, M.D.Physician-in-Chief & Executive Vice PresidentFox Chase Cancer CenterSenior Associate DeanTemple University School of MedicinePhiladelphia, PA

James M. Ford, M.D.Associate Professor of Medicine and GeneticsStanford University School of MedicineStanford, CA

Susan G. Hilsenbeck, Ph.D.Fellow of the American Statistical AssociationVice Chair, Baylor College of Medicine Institutional Review BoardBaylor College of MedicineHouston, TX

Theodore S. Lawrence, M.D., Ph.D.Chair, Radiation OncologyCo-Chair, Radiation Sciences ProgramUniversity of MichiganComprehensive Cancer Center Ann Arbor, MI

A. Thomas Look, M.D.Professor, PediatricsHarvard Medical SchoolVice Chair, Pediatric Oncology ResearchDana-Farber Cancer InstituteHarvard Cancer Center Leukemia ProgramCambridge, MA

John D. Minna, M.D.Professor and Director, Hamon Center for Therapeutic Oncology ResearchProfessor, Internal Medicine & PharmacologyDirector, Center for Cancer GeneticsUniversity of Texas Southwestern Medical CenterDallas, TX

Robert C. Bast, Jr., M.D.Vice President for Translational ResearchMD Anderson Cancer CenterHouston, TX

William T. Beck, Ph.D.Professor and HeadDepartment of Biopharmaceutical SciencesUniversity of Illinois at ChicagoChicago, IL

Gerold Bepler, M.D., Ph.D.President & Chief Executive OfficerKarmanos Cancer InstituteDetroit, MI

Lisa M. Coussens, Ph.D.Hildegard Lamfrom Chair in Basic ScienceProfessor and Chair, Cell & Developmental BiologyAssociate Director for Basic RsearchKnight Cancer InstituteOregon Health & Sciences UniversityPortland, OR

Nancy E. Davidson, M.D.DirectorUniversity of Pittsburgh Cancer InstitutePittsburg, PA

H. Shelton Earp III, M.D.Director & Lineberger ProfessorProfessor of Medicine and PharmacologyUNC Lineberger Comprehensive Cancer CenterChapel Hill, NC

Paul F. Engstrom, M.D.Senior Vice President for Population ScienceFox Chase Cancer CenterPhiladelphia, PA

Olivera J. Finn, Ph. D.Professor & Chair, Dept. of ImmunologyUniversity of Pittsburgh School of MedicinePittsburg, PA

8

Richard O’Reilly, M.D.Chair, Department of PediatricsChief, Pediatric Bone Marrow Transplant ServicesMemorial Sloan-Kettering Cancer CenterNew York, NY

Jerome Ritz, M.D.Professor of Medicine, Harvard Medical SchoolDana-Farber Cancer InstituteBoston, MA

David E. Schuller, M.D.Vice President, OSU Medical Center Expansion and OutreachDirector Emeritus, OSU Comprehensive Cancer CenterThe Ohio State UniversityColumbus, OH

Jonathan W. Simons, M.D.Chief Executive OfficerProstate Cancer FoundationSanta Monica, CA

Margaret A. Tempero, M.D.Chief, Medical Oncology Department of MedicineUniversity of California at San FranciscoSan Francisco, CA

Martin D. Abeloff, M.D.In Memoriam

Joseph O. Moore, M.D.Medical DirectorDuke Raleigh Cancer CenterProfessor, Hematology & Oncology Department of MedicineDuke Cancer InstituteDurham, NC

William G. Nelson, M.D., Ph.D.Professor, Oncology and UrologyDirectorSidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimore, MD

Brian Patrick O’Neill, M.D.Professor of Neurology, Mayo ClinicCollege of MedicineLeader, Translational Research Program in Neuro-OncologyDirector, Mayo SPORE in Brain CancerMayo Clinic Cancer CenterRochester, MN

David Piwnica-Worms, M.D., Ph.D.Director, BRIGHT InstituteDirector, Molecular Imaging CenterProfessor of Radiology, Cell Biology & Physiology, Developmental BiologyWashington University School of MedicineSt. Louis, MO

Helen Piwnica-Worms, Ph.D.Gerty T. Cori Professor and Head of Cell Biology & PhysiologyProfessor of Internal MedicineWashington University School of MedicineSt. Louis, MO

9

”

“— Dr. robert bast

The V FOunDaTiOn scienTiFic aDVisOry bOarD is an excepTiOnal GrOup OF physicians anD scienTisTs whO assure ThaT FunDs FrOM DOnOrs are inVesTeD wisely

in The careers OF The MOsT GiFTeD anD MOTiVaTeD yOunG inVesTiGaTOrs anD in The MOsT prOMisinG

prOjecTs which MOVe new DruGs anD apprOaches FrOM The labOraTOry TO The clinic.

current assets

Cash and cash equivalents

Accounts receivable, net

Promises to give, net

Prepaid expenses

total current assets

property & equipment, net

other assets

Investments

Promises to give, net

total other assets

total assets

support and revenue

Contributions and gifts

Special events income, net of expenses

Investment income

Unrealized gain on investments

Realized gain on investments

Net assets released from restrictions

total support and revenue

expenses

Program Services

supporting services

Management and general

Fundraising expenses

total supporting services

subtotal expenses

Loss from bad debts

total expenses

changes in net assets

net assets - beginning of year

net assets - end of year

current liabilities

Accounts payable & accrued expenses

Accrued payroll & related liabilities

Lease payable

Grants payable

total current liabilities

long-term liabilities

Grants payable, net

total liabilities

net assets

Unrestricted

Temporarily restricted

Permanently restricted

total net assets

total liabilities and net assets

sTaTeMenT OF Financial pOsiTiOn September 30, 2012

sTaTeMenT OF acTiViTies & chanGes in neT asseTsFor the Year Ended September 30, 2012

assets liabilities and net assets

$11,413,695

55,500

316,918

56,406

11,842,519

38,177

21,026,926

3,874,888

24,901,814

$36,782,510

$5,970

33,164

27,350

10,897,500

10,963,984

9,434,728

20,398,712

(3,207,040)

3,834,726

15,756,112

16,383,798

$36,782,510

unrestrictedtemporarily

restrictedpermanently

restricted totals

$9,287,602

3,827,663

138,643

320,457

112,857

13,687,222

2,908,465

16,595,687

15,537,636

724,916

769,755

1,494,671

17,032,307

–

17,032,307

(436,620)

(2,770,420)

($3,207,040)

$2,533,706

–

–

–

–

2,533,706

–

2,533,706

–

–

–

–

–

80,000

80,000

2,453,706

13,302,406

$15,756,112

$936,206

–

322,984

813,615

286,511

2,359,316

(2,908,465)

(549,149)

–

–

–

–

–

150,000

150,000

(699,149)

4,533,875

$3,834,726

$12,757,514

3,827,663

461,627

1,134,072

399,368

18,580,244

–

18,580,244

15,537,636

724,916

769,755

1,494,671

17,032,307

230,000

17,262,307

1,317,937

15,065,861

$16,383,798

20

12 F

INA

NC

IALS

10

11

ca

TOP 15 GRANT DISTRIBUTIONSBY STATE, 1994-2012

ny

Va

nc

pa

Mn

Ma

MD

in

Tx

Tn

Oh

nj

Fl

il

$20,296,312

$6,179,861

$2,202,650

$11,170,954

$5,456,709

$1,804,322

$10,900,000

$4,956,200

$1,729,175

$7,684,697

$3,000,000

$3,852,017

$1,450,000

$7,661,860

$2,505,750

176

GRANT DISTRIBUTIONS BY CANCER SITE, 1994-2012

26

496

66

24

53

17

45

10

13

31

grants

grants

grants

grants

grants

grants

grants

grants

grants

grants

grants

General Cancer/Other$21,393,992

GI$3,776,562

$101,391,054

Leukemia/Lymphoma$17,375,000

Prostate$4,410,000

Breast$10,515,000

Melanoma$6,250,000

Pediatric$13,159,000

Pediatric$13,159,000

Pancreatic$5,050,000

7

6

6

3

5

grants

grants

grants

grants

grants

Renal$2,686,500

Head and Neck$1,350,000

Myeloma $500,000

Colon$350,000

Ewings$775,000

Lung$8,850,000

8grants

Gyn./Cervical/Ovarian $1,900,000

10grants

Brain$3,050,000